Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019)

Praxis Precision Medicines' (PRAX) quarterly Preferred Stock Liabilities came in at $121.1 million in Q4 2019.

Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019) Analysis & Trends

Praxis Precision Medicines' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $121.1 million for Q4 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $121.1 million in Q4 2019; TTM through Dec 2019 was $121.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $121.1 million, changed N/A from the prior year.
  • Preferred Stock Liabilities was little changed at $121.1 million in Q4 2019 per PRAX's latest filing.
  • Across five years, Preferred Stock Liabilities topped out at $121.1 million in Q4 2019 and bottomed at $121.1 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Praxis Precision Medicines 8.98 Bn 8.20 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2019 121.12 Mn